With some signs of a turnaround in the national and regional economy, cautious optimism seems to be taking hold in the investment community. Is it justified? How will changes in national, state and regional financial structures affect the outlook for 2014 and for your business?
We will start this program with PwC’s acclaimed Moneytree report, detailing the amounts, sources, and sectors for venture capital investment. This is always one of our most popular sessions and PwC has just released their 2013 report.
Opportunities to raise early and mid stage investment capital have also diversified beyond traditional venture capital.
In this program, we have put together a panel of various types of investors (an angel, a venture capitalist, a strategic investor, and a debt investor) to review the different sources of early and mid-stage capital, and will review the major economic events of 2013 and discuss their forecasts for the investment climate in 2014.
The program will be moderated by long term start-up veteran and partner from Wilson, Sonsini, Goodrich, and Rosati, Mr. Marty Waters.
Glenn Bier - Partner, PricewaterhouseCoopers
Glenn is an assurance partner in our Southern California technology practice with over 17 years of experience. He has worked extensively with clients in the software, hardware, semiconductor, Internet, telecommunications, life sciences and entertainment industries. His clients have included a wide range of companies from multi-national publicly traded corporations with significant foreign operations to emerging companies, including venture-backed entities.
Andy Corley - Principal, Yelroc Consulting Inc.
Andy Corley co-founded eyeonics, Inc. in 1998. eyeonics developed and gained approval of a new category of intraocular lenses, the accommodating IOL. Mr. Corley’s 5-year effort changed CMS policy to allow Medicare beneficiaries a choice in the selection of their intraocular lens associated with cataract surgery. eyeonics was sold to Bausch and Lomb in 2008 where Mr. Corley served as President of the Surgical Division. He was co-founder of Chiron Ophthalmics, where he was General Manager of the Refractive Surgery Division until 1997. During his term at Chiron, he played a key role in the introduction of LASIK. In 2005 he was the Orange County Entrepreneur of the Year and the Crystalens was declared the AeA Technology of the Year. In 2011 Mr. Corley formed Yelroc Consulting Inc. He is past Chairman of the Board of Technolas Perfect Vision and Executive Chairman of NeoVista Inc. He serves on the advisory boards of the Scripps Genomic Institute. He is a graduate of Georgia Southern University.
Carol Gallagher - Venture Partner, Frazier Healthcare
Dr. Gallagher joined Frazier Healthcare’s life science team in October of 2013 as a Venture Partner. Prior to Frazier, Dr. Gallagher was President and CEO of Calistoga Pharmaceuticals, a Frazier-founded company based on a set of novel, preclinical assets spun out of Icos Pharmaceuticals. Dr. Gallagher together with an experienced team she helped to build, advanced a first-in-class product (CAL-101, now called idelalisib) through definitive, proof-of-concept studies in patients with certain lymphomas and leukemias. These efforts ultimately led to the acquisition of Calistoga by Gilead Sciences in 2011 for a total consideration of $600 million. Dr. Gallagher currently serves on several biotech boards, including AnaptysBio and Atterocor, both of which are Frazier portfolio companies. She also serves as Chairman for eFFECTOR Therapeutics and Atara Bio.Dr. Gallagher attended Vanderbilt University and received Bachelor of Science and Doctor of Pharmacy degrees from the College of Pharmacy at the University of Kentucky. She started her career at Eli Lilly and Company and held roles of increasing responsibility with Amgen, Agouron/Pfizer, Biogen Idec, CancerVax and Anadys Pharmaceuticals.
Derek Hoyt - Senior Technology Banker, Silicon Valley Bank
Derek Hoyt is a senior Technology banker who has been actively working with both private and public innovation companies since 1998. In August 2013 Derek took over SVB’s Growth Technology team for its Orange County office, focusing on software, IT, Digital Media, Cloud, Healthcare IT, & other innovation companies from startup and $100 million in annual revenues. Prior to that he had spent 6 years structuring credit facilities for SVB clients and prospects across the Southern California region. Representative credit facilities include venture debt, asset based, cash flow and recurring revenue financing to support growth, M&A, and working capital financings. Derek earned his degree Business Administration with a Finance emphasis from San Diego State University in 1998.
Jane Rady - Divisional Vice President, Business Development, Abbott Medical Optics
Jane E. Rady is Divisional Vice President, Business Development and Communications at Abbott Medical Optics (AMO). Prior to AMO’s acquisition by Abbott in 2009, Jane served as Executive Vice President, Strategy and Corporate Development at Advanced Medical Optics from February 2007 to February 2009. From April 2006 to February 2007, she was Corporate Vice President, Strategic and Corporate Development, and from April 2002 to April 2006, she was Corporate Vice President, Strategy and Technology. Prior to joining AMO, Ms. Rady was a Director and the CEO of Integrated Genomics, Inc. and was a consultant to Integrated Genomics and several other companies in 2001. From 1984 to 2000, Ms. Rady was employed by G.D. Searle & Co./Monsanto in various capacities including President and General Manager of Searle’s international joint venture, Lorex Pharmaceuticals Ltd., Vice President of Corporate Licensing & Business Development, and Vice President of Strategic Planning.
Martin Waters - Partner, Wilson Sonsini Goodrich & Rosati
Martin (Marty) Waters is a corporate and securities partner in the San Diego office and a former member of the firm's Policy Committee. He is a founding partner of the firm's San Diego office and Southern California corporate practice. He was a partner in the Palo Alto office until opening the San Diego office in 2004. Marty is a proven company builder with nearly 20 years of experience providing corporate and securities counsel. He has been instrumental in starting, building, and shepherding through initial public offering or sale numerous emerging growth companies in a broad range of industries, including biotech, clean technology, cloud computing, e-commerce, medical device, new and traditional media, SaaS, semiconductors, social networking, and telecommunications. A partial list of exited emerging growth clients includes Ablation Frontiers, CoreValve, Cytokinetics, evite, eyeonics, Helixis, Heritage Pharma, Illumina, Indigo Systems, Lara Networks, N Spine, Optimer Pharmaceuticals, Pain Therapeutics, SKS Microfinance, TearLab, and TweetPhoto. Marty also represents several public companies in a general counsel capacity, as well as investment banks and placement agents in PIPEs and public offerings. Marty has counseled issuers and underwriters in more than 50 offerings while at Wilson Sonsini Goodrich & Rosati and with Cahill Gordon & Reindel and Akin Gump Strauss Hauer & Feld in New York.
For sponsorship opportunities please contact Christina@octaneoc.org
Cocktails and hors d'oeuvres will be served.
Networking Opportunities: OCTANe programs provide some of the best networking opportunities available in Southern California. Attendees include entrepreneurs, researchers, inventors, investors, corporate executives, and strategic service providers.
In order to purchase these tickets in installments, you'll need an Eventbrite account. Log in or sign up for a free account to continue.